Preclinical studies have demonstrated that RTA 408 possesses antioxidative and anti-inflammatory activities,[12][13] as well as the potential to improve mitochondrial bioenergetics.

[18][19] Reata is also actively engaged in the discovery of small molecule disease-modifying drugs that function by stabilizing the normal three-dimensional structure of target proteins or generally enhancing the folding environment of the cell.

Protein folding defects are also believed to play important roles in the development of non-inherited forms of many of these diseases.

Reata has a licensing agreement with Kyowa Hakko Kirin for development and commercialization of bardoxolone methyl for CKD and related indications in Japan, China, Taiwan, Korea, and other select Southeast Asian countries.

[21] Abbvie and Reata also have a second agreement for development of the second generation portfolio of synthetic oleanane triterpenoid compounds, including RTA 408, as well as other Nrf2 activators.